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Abstract
Enhanced leukocytic infiltration into pancreatic islets contributes to inflammation-based 
diminutions in functional β-cell mass. Insulitis (aka islet inflammation), which can be present in 
both T1DM and T2DM, is one factor influencing pancreatic β-cell death and dysfunction. IL-1β, 
an inflammatory mediator in both T1DM and T2DM, acutely (within 1h) induced expression of 
the CCL20 gene in rat and human islets and clonal β-cell lines. Transcriptional induction of 
CCL20 required the p65 subunit of NF-κB to replace the p50 subunit at two functional κB sites 
within the CCL20 proximal gene promoter. The NF-κB p50 subunit prevents CCL20 gene 
expression during unstimulated conditions and overexpression of p50 reduces CCL20, but 
enhances cyclooxygenase-2 (COX-2), transcript accumulation after exposure to IL-1β. We also 
identified differential recruitment of specific co-activator molecules to the CCL20 gene promoter, 
when compared with the CCL2 and COX2 genes, revealing distinct transcriptional requirements 
for individual NF-κB responsive genes. Moreover, IL-1β, TNF-α and IFN-γ individually increased 
the expression of CCR6, the receptor for CCL20, on the surface of human neutrophils. We further 
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found that the chemokine CCL20 is elevated in serum from both genetically obese db/db mice and 
in C57BL6/J mice fed a high-fat diet. Taken together, these results are consistent with a possible 
activation of the CCL20-CCR6 axis in diseases with inflammatory components. Thus, interfering 
with this signaling pathway, either at the level of NF-κB-mediated chemokine production, or 
downstream receptor activation, could be a potential therapeutic target to offset inflammation-
associated tissue dysfunction in obesity and diabetes.
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1.1 Introduction
Type 1 (T1DM) and Type 2 diabetes mellitus (T2DM) are endocrine diseases associated 
with inflammation in several tissues, including pancreatic islets [1–3]. Pro-inflammatory 
cytokines, such as IL-1β and IFN-γ, initially impair islet β-cell function and are ultimately 
cytotoxic [4–6]. Pancreatic β-cells express high levels of the interleukin-1 receptor I 
(IL-1RI), making them exquisitely sensitive to IL-1β [5, 7]. Indeed, transcriptional 
reprogramming of pancreatic β-cells begins as early as one hour after exposure to IL-1β and 
induces expression of genes encoding inducible nitric oxide synthase, cyclooxygenase-2 [8–
10] and various chemokines [2, 11–14]. Activation of the NF-κB pathway is central to 
transcriptional initiation of these genes and corresponding inflammatory responses.
The NF-κB family of transcription factors participates in diverse conditions associated with 
pathological outcomes, including aging [15], arthritis [16], cancer [17], neuroinflammation 
[18, 19], and metabolic disease [1]. There are five NF-κB subunits, designated as p65 
(RelA), RelB, c-Rel, p50 (NFKB1), and p52 (NFKB2). Homo- and hetero-dimers consisting 
of combinations of these individual subunits are assembled after cellular exposure to 
specific stimuli [20]. Prior to such a stimulus, inhibitors of kappa B proteins (IκBs) 
specifically sequester NF-κB transcriptional regulators in the cytoplasm. Receptor activation 
promotes signaling cascades that lead to phosphorylation-induced degradation of the IκBs. 
This degradation exposes a nuclear localization signal within particular subunits (e.g., p65), 
culminating in nuclear accumulation of transcriptionally competent dimers [21]. Once in the 
nucleus, these dimeric NF-κB transcription factors recognize defined genomic response 
elements (i.e., κB sites) to initiate transcription.
The highly specific and controlled transcriptional activation of NF-κB target genes is a 
major route to tissue inflammation. Examples of such genes include the chemokine family 
of soluble secreted proteins that coordinate immune cell recruitment and activation in sites 
of inflammation [22, 23]. For example, elevation of CCL2 is associated with an increase in 
adipose tissue macrophages and CCL2 abundance positively correlates with body mass 
index [24, 25]. In addition, transgenic overexpression of CCL2 directly from pancreatic β-
cells is sufficient to produce insulitis (i.e., islet inflammation) and diabetes [26]. In addition 
to CCL2, a wide variety of other chemokines are induced in rodent and human islets 
exposed to IL-1β [11, 27]. The ensuing increase in global chemokine receptor signaling 
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upon response to these chemokines is associated with both pathological inflammation and 
poor islet transplant outcomes [28, 29].
The gene encoding the chemokine CCL20 (previously called exodus-1, LARC, and MIP-3α) 
was originally cloned from human pancreatic islet tissue [30]. Since its initial cloning, 
CCL20 has been implicated in a diverse set of inflammatory conditions, including 
rheumatoid arthritis [31], multiple sclerosis [32] and islet viral infection [33]. Indeed, 
CCL20 is able to chemoattract both adaptive and innate immune cells, including CD4+ and 
CD8+ T-cells [34, 35], dendritic cells [36], B-lymphocytes [37, 38] and natural killer (NK) 
cells [39]. Collectively, these data place CCL20 as a probable contributor to the 
development of T1DM, T2DM, or both endocrine diseases. However, very little is known 
about the role of CCL20 in obesity and diabetes and the molecular mechanisms mediating 
CCL20 gene regulation in pancreatic β-cells are poorly understood.
Herein, we demonstrate that CCL20 abundance is increased in islets from obese mice and 
that IL-1β strongly and rapidly promotes expression of the CCL20 gene in rat and human 
pancreatic β-cells. This transcriptional activation results from the highly-regulated and 
opposing activity of the p65 and p50 subunits of NF-κB. The fact that serum levels of 
CCL20 are elevated in both genetically obese db/db mice as well as in C57BL6/J mice on a 
high-fat diet provides links between obesity, CCL20, islet inflammation, and diabetes. 
Finally, we also report that inflammatory cytokines promote surface expression of CCR6, 
the only known receptor for CCL20 [40], in human peripheral blood neutrophils. 
Neutrophils are critical for initiating autoimmune-mediated β-cell destruction in NOD mice 
[41] and also accumulate in the human pancreas prior to diabetes onset [42, 43]. Thus, our 
results provide evidence that inflammatory signals presently linked with the development of 
obesity and diabetes also enhance CCL20 production in islet β-cells and induce the 
corresponding receptor (CCR6) on human neutrophils.
2.1 Materials and Methods
2.1.1 Cell culture, islet isolation and reagents
Culture and passage of the 832/13[44] and INS-1E [45] rat insulinoma cell lines have been 
described. Human islets were from obtained via Lonza (Clonetics™ Fresh Human 
Pancreatic Islets). All reagents were from Fisher Scientific, unless otherwise noted.
2.1.2 Animal Models, Pancreatic Islet Isolation, and RNA extraction from Isolated Mouse 
Islets
Seven week old male lean (db/+) and obese (db/db) mice (B6.BKS(D)-Leprdb/J) were 
obtained from the Jackson Laboratory and housed for one week with free access to food and 
water prior to isolation of islets. For the islet isolation, eight week old mice were first 
euthanized via CO2 asphyxiation followed by a cervical dislocation. Blood was collected via 
cardiac sticks and was used in ELISA assays for determination of serum CCL2 and CCL20 
levels. Blood was also collected from 24 week old C57BL6/J mice fed ad libitum for 18 
weeks with purified diets containing different fat contents (10, 25, and 60% kcal). All 
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procedures were approved by the appropriate PBRC, Duke University, or UT Medical 
Center animal care and use committees.
For isolation of mouse islets, a 20 mL collagenase solution was prepared containing 1X 
HBSS, 4 mM sodium bicarbonate, 375 µL cold 1M HEPES buffer (Gibco, Grand Island, 
NY), 90 µg DNase 1 (Roche, Indianapolis, IN), and 0.18 mg Liberase TL (Roche). The 
ampulla of Vater was cannulated and the collagenase solution slowly infused into the 
common bile duct to perfuse the pancreas. After perfusion, the pancreas was excised and 
placed in a 50 mL Falcon tube containing 7 mL of the enzyme solution. The pancreas was 
periodically shaken while incubating for 15 minutes in a 37°C water bath. After 15 minutes, 
the pancreas was shaken vigorously for ten seconds before digestion was stopped with ~40 
mL of quenching buffer (1X HBSS, 4 mM sodium bicarbonate, 27.5 mL fetal bovine serum 
(FBS), and 50 µL DNase at 100 mg/mL). This mixture was plunged several times through a 
14 g blunt tipped needle to further homogenize the tissue. The homogenate was passed 
through a 400 µm screen (Bellco, Vineland, NJ) into a new Falcon tube to filter out large 
pieces of undigested exocrine tissue. The tube was spun at 250 × g at 4°C for 3 minutes, 
after which the supernatant was discarded. The pellet was suspended in a separate Falcon 
tube with 7 mL of a Polysucrose 400 (Fisher Scientific, Pittsburgh, PA) solution at 1.109 
g/mL. A gradient was then produced by carefully layering 7 mL of 1.096 g/mL on top, 
followed by 1.070 g/mL and 0.570 g/mL. The gradient was spun at 1000 × g for 20 minutes 
at 4°C. The islets were located at the interface between the 1.070 g/mL and 0.570 g/mL 
layers, and a bulb pipette was used to extract the islets from the layer and into a new tube 
containing 40 mL of quenching buffer. The islets were washed in quenching buffer by 
centrifuging at 250 x g for 3 minutes. The supernatant was discarded and the wash step was 
repeated. The resulting pellet was suspended in 10 mL of RPMI 1640 media (11 mM 
glucose) supplemented with 10% FBS, penicillin (100 units/mL), streptomycin (100 µg/mL), 
and amphotericin B (2.5 µg/mL), and subsequently plated. Isolated islets were imaged using 
an Olympus CK40 inverted microscope and incubated at 37°C and 5% CO2 for ~24 hours. 
Isolation of rat islets has been described previously [46].
After 24 h of incubation following isolation, the islets were hand-picked into a clean 6-well 
plate, cultured an additional 24 h, then treated as described in the figure legends, suspended 
in 300 µL of RLT buffer and frozen at −80°C. RNA was isolated using Qiagen RNeasy 
microkit according to the manufacturer.
2.1.3 Construction of plasmids
A 3kb PCR product corresponding to −3kb of the rat CCL20 promoter was generated using 
the following primer sequences: (F): 5’aaaaaACGCGTTGTGGCCAATGTTCTAGTTGAC 
3’ and (R): 5’aaaaa CTCGAGTTACACACTCCTTAGCAGGTTG 3’. The PCR product 
was digested with MluI and XhoI restriction enzymes and then inserted into the pGL3 
luciferase reporter plasmid between the MluI (ACGCGT) and XhoI (CTCGAG) restriction 
sites. The cloned and verified −3kb promoter sequence was deposited in GenBank 
(Accession # KC572139.1).
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Proximal and distal NF-κB mutations in the −3kb-luciferase plasmid were generated by site-
directed mutagenesis using the QuikChange Site-Directed Mutagenesis kit according to 
manufacturer’s instructions (Agilent Technologies). The following primer pairs were used to 
incorporate these mutations (mutations are in bold, underlined, and lowercase): proximal 
NF-κBm: (F) 5’CAGATTAATCAATGGGG cc AAACCCCGGGTGAGAAC 3’ and (R) 5’ 
GTTCTCACCCGGGGTTT gg CCATTGATTAATCTG 3’, distal NF-κBm #1: (F) 
5’GCTCTCATTGGTGAGGG cc CTTTACTTCCTGTCTTC 3’ and (R) 
5’GAAAGACAGGAAGTAAAG gg CCCTCACCAATGAGAGC 3’ and distal NF-κBm 
#2: (F) 5’ CTCTCATTGGTGAG tt GA aa TTACTTCCTGTCTTTCTCG 3’ and (R) 5’ 
CGAGAAAGACAGGAAGTAA tt TC aa CTCACCAATGAGAG 3’. Mutations were 
confirmed by DNA sequencing at the Pennington Biomedical Research Center Genomics 
Core Facility.
WT Mutant
proximal NF-κB GGGAAAACCC GGccAAACC
distal NF-κB GGGACTTTAC Mut #1: GGccCTTTAC
Mut #2: ttGAaaTTAC
2.1.5 Transfection and Luciferase Assays
Transient transfection of plasmid vectors into 832/13 cells was performed using TransFectin 
Lipid Reagent (Biorad) according to the manufacturer’s instructions. Following the 
transfection, cells were lysed in 1x Passive Lysis Buffer (Promega) and luciferase activity 
was measured using the Luciferase Assay System (Promega) in a GloMax plate reading 
luminometer (Promega). Luciferase activity was normalized to total protein content as 
determined by BCA assay (Promega).
2.1.6. RNA isolation, cDNA synthesis and real-time RT-PCR
RNA was isolated from cells using Isol-RNA Lysis Reagent (5 Prime Inc., Gaithersburg, 
MD) and from human, rat and mouse islets using the RNeasy kit (QIAGEN). cDNA 
synthesis and real-time PCR analysis were as described (AJP). Primers used to detect 
mRNA abundance of RS9, Ccl20, Ccl2 and Cox2 were designed using Primer3Plus software 
and are available upon request. Transcript abundance was normalized to the housekeeping 
gene Ribosomal S9 (RS9).
2.1.7 ELISA
Circulating levels of CCL2 and CCL20 were analyzed using serum samples from C57BL/J 
and db/db mice obtained from the Jackson Laboratories. For in vitro experiments, the release 
of CCL2 and CCL20 into cell culture medium was detected. All samples were analyzed 
using R&D Quantikine ELISA kits (R&D systems, Minneapolis, MN) according to the 
manufacturer’s protocol. Release of CCL2 and CCL20 into the culture medium was 
normalized to total protein to account for any potential variability in cell number.
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2.1.8 Protein isolation and immunoblotting
Whole-cell lysate preparation and immunoblotting were performed as described [13]. 
Antibodies used were from the following sources: anti-p65 (#8242), anti-p50/105 (#12540), 
and anti- β-Actin (#8457) were all from Cell Signaling Technology while anti-IκBα (sc-371) 
was from Santa Cruz.
2.1.9 Chromatin Immunoprecipitation
832/13 cells were cultured in 15-cm dishes, using one dish per treatment condition. After 
treatment of cells as indicated in the figure legends, the culture medium was aspirated, 
formaldehyde was added at a final concentration of 1% in PBS and incubated at room 
temperature for 10 minutes. At the end of the crosslinking, glycine was added to a final 
concentration of 125 mM for 5 minutes at room temperature. Cells were washed once with 
cold PBS and scraped into 1-mL prechilled PBS with 1× protease inhibitors (Halt Protease 
Inhibitor Cocktail; Thermo Fisher Scientific). Cell pellets were collected by centrifugation at 
1000g for 5 minutes at 4°C. Supernatants were discarded, and pellets were reconstituted in 
0.5 mL of SDS lysis buffer containing 1× protease inhibitors (1% SDS, 10 mM EDTA, and 
50 mM Tris-HCl; pH 8.0). Lysates were incubated on ice for 15 minutes, and then DNA was 
sheared by sonication using a Bioruptor Pico (Diagenode). The following sonication 
conditions generated fragments of DNA between 100 and 500 bp in length: cycle on: 30 
seconds, cycle off: 30 seconds for a total of 90 cycles. Sonicated fragments were centrifuged 
at 12,000g for 10 minutes at 4°C, and supernatants were transferred to a clean 
microcentrifuge tube. Dynabeads were prepared as follows: once resuspended, 10 µL of 
beads were transferred to a new microcentrifuge tube for each condition. The tubes were 
placed in a magnetic rack to separate the beads out of solution, and supernatants were 
removed. 1 µg antibody in 200 µL PBS with 0.02% Tween-20 was added to the beads and 
incubated for 10 mins at RT with rotation. Tubes were placed on the magnetic rack and 
supernatants were removed. Bead-antibody complexes were washed with 200 µL PBS with 
0.02% Tween-20. 250 µg of sheared cross-linked DNA was diluted 10-fold in dilution buffer 
containing 1 × protease inhibitors (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 167 
mM NaCl, and 17 mM Tris, pH 8.0), added to tubes containing dynabead-antibody 
complexes and incubated overnight at 4°C with rotation. The following day, dynabead-
antibody-chromatin complexes were washed sequentially with 0.5 mL of the following 
buffers: 1× low-salt buffer, (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and 
20 mM Tris; pH 8.0), 1× high-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 
mM NaCl, and 20 mM Tris; pH 8.0); and 1× LiCl buffer (0.25 M LiCl, 1% NP-40, 1 mM 
EDTA, and 10 mM Tris; pH 8.0), and 2× Tris EDTA. Once the last wash buffer was 
completely removed, 100 µL of 10% Chelex-100 resin in PBS was added, vortexed for 10 s, 
and heated to 100°C for 10 minutes. After centrifugation at 17,000g for 1 minute at 4°C, the 
supernatants were transferred to new tubes. Then 120 µL of RNase and DNase-free water 
was added, vortexed for 10 s, and centrifuged at 17,000g for 1 minute at 4°C. Supernatants 
were pooled. Inputs were processed as followed: 20 µL of sonicated, precleared DNA was 
incubated overnight at 65°C with NaCl to a final concentration of 200 mM. Input DNA was 
then treated with RNase A for 30 minutes at 37°C and proteinase K for 1 hour at 45°C and 
then purified using a QIAGEN Cleanup kit (QIAGEN); 2.5 µL of the purified DNA was 
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used as a template for PCR. Primer sequences for amplifying the Ccl20, Ccl2 and Cox2 NF-
κB elements and coding regions were generated using Primer3Plus software and are 
available upon request. Antibodies used for immunoprecipitation were from Santa Cruz 
Biotechnology, Inc. (p65 and p50) while normal rabbit serum (IgG) was obtained from 
Sigma-Aldrich.
2.1.10 Pancreas Histology and Immunohistochemistry
Pancreata were fixed via immersion in 10% neutral buffered formalin for 48 hours prior to 
paraffin processing, embedding, and sectioning at three microns. All immunohistochemistry 
steps were performed on a Leica Bond Max auto-immunostainer running a modified IHC 
protocol. Briefly, slides were dewaxed and subjected to HIER using Leica’s epitope retreival 
solution 2 (ER2, pH 9.0) for 20 minutes prior to primary antibody incubation (abcam anti-
CCL20 [ab9829], 1:100 dilution) for 1 hr. Detection was accomplished using Leica’s Bond 
Polymer Refine Detection Kit and a modified “Protocol F” by incubating with anti-rabbit 
polymer for 8 minutes followed by a peroxide block for 5 minutes, 10 minutes of DAB 
reagent, and then counterstain with hematoxylin for 5 minutes.
2.1.11 Human PBN Isolation and Stimulation
Human PBNs were isolated from EDTA-treated blood from healthy human volunteers using 
dextran sedimentation and density gradient centrifugation as previously described [47]. 
PBNs were re-suspended in PBS and stimulated with 1ng/ml of either IL-1β, TNF-α, or 
IFN-γ or left unstimulated for 30min at 37°C. Cell surface expression of CCR6 and CXCR2 
was measured by a FACScalibur (BD Biosciences) instrument after staining with 
monoclonal antibodies (Biolegend) and data analyzed using FlowJo software (v10). The use 
of human subjects has been approved by the University of Tennessee Institutional Review 
Board (IRB# 6476B).
2.1.12 Statistics
One way ANOVA with Tukey’s post hoc test or Student’s t-test was performed using 
GraphPad Prism 6.0. The corresponding p values are given in the figure legends.
3.1 Results
3.1.1 IL-1β increases CCL20 gene transcription in rat and human islets and β-cell lines
IL-1β is one of the major cytokines leading to islet inflammation in T1DM and T2DM [48] 
and global deletion of the IL-1RI reduces metabolic sequelae that arise due to high-fat 
feeding [49]. In INS-1E cells, a rat insulinoma cell line, 1ng/mL IL-1β increased the 
abundance of CCL20 mRNA 175-fold over the untreated control (Figure 1A). Similar 
results were obtained using isolated rat islets (322-fold increase; Figure 1B) and isolated 
human islets (198-fold increase; Figure 1C). Exposure to IFN-γ alone did not induce 
expression of the CCL20 gene and the combination of IFN-γ plus IL-1β was unable to 
augment transcript levels over IL-1β alone (Figure 1A–C).
Time course analysis revealed that the CCL20 gene was induced as early as one hour after 
exposure to IL-1β (Figure 1D). This observation was confirmed in both isolated rat islets 
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(Figure 1E) and human islets (Figure 1F), where CCL20 mRNA synthesis increased as early 
as 1h with a peak at 3h post-IL-1 exposure. This rapid and robust increase in CCL20 
expression is not dependent on new protein synthesis, indicating CCL20 is a primary 
response gene in pancreatic β-cells. Indeed, inhibition with cycloheximide had no effect on 
IL-1β-mediated transcript accumulation (data not shown). Because the two clonal rat β-cell 
lines, rat islets and human islets all display similar responses after IL-1β exposure, the 
832/13 rat β-cell line was used for the remainder of the studies presented below.
3.1.2 The RelA/p65 subunit of NF-κB is required for expression of the CCL20 gene
The CCL20 gene is a primary response gene in pancreatic β-cells (Figure 1). Using in silico 
analysis, we identified two potential κB genomic elements within −3kb (relative to the 
transcriptional start site) of the CCL20 gene promoter (Figure 2A). We cloned this −3kb 
proximal promoter region, which contains both of the predicted κB responsive elements 
shown in Figure 2A, into a luciferase reporter vector. This reporter construct displayed a 33-
fold increase in transcriptional activity after exposure to IL-1β (Figure 2B).
To investigate the importance of the κB responsive elements, we generated multiple 
mutations within these two predicted κB sites (Figure 2C). The wild-type promoter-
luciferase construct was induced 24.4-fold (set at 100% in Figure 2C). The transcriptional 
activity of the CCL20 gene promoter sequence was unaffected by conservative mutations 
within the distal κB element (dNF-κBm #1; Figure 2C; shown as a percentage of the wild-
type promoter). However, further divergence from a consensus κB sequence (dNF-κBm #2) 
produced a 50% decrease in IL-1β-driven promoter activity. By contrast, mutations in the 
proximal κB genomic element (pNF-κBm), a response sequence closer to the transcriptional 
start site, abolished reporter expression in response to IL-1β (Figure 2C).
Having established that functional κB sites are required to drive transcription in response to 
IL-1β, we next examined the requirement for signaling through IKKβ, a known component 
of the canonical NF-κB pathway linked to IL-1R activation [50]. Using 2-
[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA), an IκKβ 
inhibitor, there was a 69–76% decrease in IL-1β-mediated CCL20 mRNA accumulation 
over a 0.5 – 2µM concentration range (Figure 2D). We note that this concentration range of 
TPCA is sufficient to protect against cytokine-induced β-cell death [5] and also illustrates 
the importance of IκKβ in regulating transcription of the CCL20 gene.
The IKK complex phosphorylates the IκBα proteins, leading to their degradation, with 
subsequent release of p65 for translocation to the nucleus to initiate transcriptional 
activation. In order to further define the how NF-κB pathway proteins control CCL20 
expression, we expressed a mutant form of IκBα (IκBαSR; SR= super-repressor) containing 
S32A/S36A amino acid substitutions that render the protein resistant to phosphorylation-
induced degradation [51]. As expected, adenoviral delivery of the IκBαSR construct to 
832/13 cells prevented the IL-1β-mediated increase in p65 nuclear accumulation (Figure 
2E). Blocking p65 movement to the nucleus resulted in an 89% decrease in CCL20 mRNA 
abundance after cellular exposure to IL-1β (Figure 2F). Overexpression of the IκBαSR, 
relative to the βGal control, reduced CCL20 promoter activity by 77% (data not shown), 
while CCL20 secretion into the media was diminished by 54% (Figure 2G). siRNA-
Burke et al. Page 8













mediated decreases in p65 also prevented IL-1β-mediated increases in CCL20 synthesis and 
secretion (not shown). These data demonstrate the importance of the IκKβ/IκBα control of 
NF-κB transcription factors for regulation of the CCL20 gene.
3.1.3 IL-1β signaling displaces the inhibitory p50 subunit concomitant with binding of the 
p65 subunit of NF-κB to the gene promoters of CCL2 and CCL20, but not COX2
We observed increased expression of the CCL2 [14] and CCL20 (Figure 2) genes in 
pancreatic β-cells after IL-1β exposure. Because the p65 and p50 NF-κB protein subunits are 
considered to be the prototypical dimerization partners promoting stimulus-specific 
transcription [50], their occupancy at sites containing either the distal or proximal κB sites 
within the CCL20 gene promoter region was measured using chromatin immunoprecipation 
assays. CCL2 and COX2 were examined in comparison because they either do (COX2) or 
do not (CCL2) require p50 for their expression in response to IL-1β [9, 14].
We observed a time dependent increase in p65 occupancy at each of the predicted κB 
elements within the CCL20 gene promoter, which was maximal at 15 min after exposure to 
IL-1β (Figure 3A; arrows denote the regions spanned by PCR primers). By contrast, the p50 
subunit occupied these same κB genomic regions in the basal (unstimulated) state, but was 
displaced concomitant with the IL-1β-mediated arrival of p65 (compare Figures 3A and 3B 
middle panels with right panels).
To understand whether this pattern of promoter residence is consistent for other NF-κB 
target genes induced by IL-1β, we also measured the p65 and p50 occupancy on the CCL2 
and COX2 promoters. CCL2 [14, 52] and COX2 [9, 53] both contain κB responsive 
elements within their gene promoters. For CCL2, we detected a similar NF-κB subunit 
occupancy pattern as that observed for CCL20, with p65 robustly recruited to κB sites 
(Figure 3C) while p50 occupancy was lost upon IL-1β exposure (Figure 3C middle panel vs. 
right panel). By contrast, p65 and p50 were simultaneously recruited to the COX2 gene 
promoter in response to IL-1β (Figure 3D; middle and right panels). No p50 occupancy was 
detected at κB sites in the COX2 gene promoter in the basal state (Figure 3D; right panel). 
These data are consistent with our previous observations, that in response to IL-1β, p50 is 
required for expression of the COX2 [9], but not the CCL2 gene [14]. Thus, in terms of NF-
κB subunit specificity at these particular gene promoters, which are all responsive to IL-1β, 
CCL20 shows similarities for subunit binding with CCL2, while COX2 clearly displays a 
different NF-κB subunit requirement when compared to the two chemokine genes.
3.1.4 IκBαSR prevents p65, but not p50, binding to IL-1β responsive gene promoters
Because IL-1β induces rapid binding of p65 to specific κB response elements concomitant 
with displacement of p50 (Figure 3), we investigated whether restricting p65 translocation to 
the nucleus with the IκBαSR would modify the differential NF-κB subunit occupancy at the 
CCL20 and CCL2 gene promoters. IL-1β induces a 3.4-fold increase in p65 binding to the 
proximal CCL20 κB site, which is inhibited in the presence of the IκBαSR (Figure 4A). In 
addition, there is a 46% decrease in p50 occupancy at the proximal κB site after exposure to 
IL-1β; this displacement of p50 from the κB site is blocked in the presence of the IκBαSR 
(Figure 4B). Almost identical results were obtained at the CCL20 distal κB site (Figures 4C 
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and 4D). We interpret these results to indicate the p65 replaces p50 at the CCL20 gene 
promoter, an event that is prevented by restricting p65 to cytosol.
For the CCL2 gene, IκBαSR also blocked p65 recruitment to κB sites (Figure 4E), which is 
consistent with the decreased expression of the CCL2 gene by this maneuver [14]. The p50 
subunit binding to the CCL2 in the basal state was reduced by 65% after exposure to IL-1β 
and this IL-1β-mediated displacement of p50 was fully reversed in the presence of the 
IκBαSR (Figure 4F). In contrast, the COX2 promoter had a 38% reduction in p65 occupancy 
during overexpression of the IκBαSR (Figure 4G) with no alterations in p50 occupancy 
(Figure 4H). Thus, there are consistent requirements for CCL20 and CCL2 responses to 
IL-1β, which differ from NF-κB subunit occupancy during COX2 transcriptional activation.
3.1.5 Overexpression of p50 markedly decreases the IL-1β-mediated expression of the 
CCL20 gene, but enhances the expression of the gene encoding COX2
Overexpression of the NFKB1 gene produces the 105kDa protein that is constitutively 
processed into the 50kDa p50 subunit (see ref [54] and Figure 5A). Because p50 occupies 
the promoter region of CCL20 and CCL2 during the basal state, we next investigated 
whether enhancing the abundance of p50 was sufficient to block the IL-1β-mediated gene 
expression. To test this possibility, we overexpressed the p50 subunit using adenoviral 
transduction. CCL2 and COX2 were once again used for comparison purposes. Using the 
three highest viral concentrations driving expression of p50 (shown in Figure 5A), we 
observed a dose-dependent reduction (26%, 58%, and 77%, respectively) in IL-1β-mediated 
CCL20 mRNA levels (Figure 5B) and a 29%, 41%, and 46% suppression of CCL2 gene 
expression (Figure 5C). By contrast, expression of the COX2 gene was enhanced by 2.49-, 
3.47, and 3.31-fold by the combination of p50 overexpression and IL-1β stimulation (Figure 
5D). There was a 90% reduction in IL-1β– driven CCL20 promoter activity with p50 
overexpression (Figure 5E). This decrease in transcription resulted in a 64%, 66%, and 74% 
reduction in secreted CCL20 protein (Figure 5F).
The ability of p50 overexpression to repress the expression of the CCL20 gene cannot be 
explained by simply restricting p65 to the cytoplasm (Figure 5G). Instead, overexpression of 
the NFKB1 gene, which leads to elevated p50 abundance, blunted the ability of IL-1β to 
drive expression of the CCL20 and CCL2 genes, while enhancing the expression of the 
COX2 gene. This is a clear demonstration of distinct functional outcomes that occur via 
placement of NF-κB subunits at discrete IL-1β-inducible, NF-κB regulated genes.
In order to discern whether elevations in p50 abundance modify p65/p50 occupancy at κB 
genomic elements, we next measured occupancy of each subunit in the presence or absence 
of p50 overexpression. Overexpression of p50 completely blocked the IL-1β-induced 
recruitment of p65 to the proximal κB site within the CCL20 gene promoter region (Figure 
6A). The displacement of p50 by IL-1β is also prevented by the presence of overexpressed 
p50 (Figure 6B). Similar results were observed at the distal κB site where overexpression of 
p50 blocked p65 recruitment (Figure 6C) as well as reversed the IL-1β-mediated exclusion 
of p50 (Figure 6D). Similarly, at the CCL2 gene promoter, p50 overexpression blocked the 
p65 recruitment normally induced by IL-1β (Figure 6E). Indeed, there is 46% more p50 
associated with the CCL2 promoter after p50 overexpression when compared to the βGal 
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control (Figure 6F). We note that there is not a complete restoration of p50 associated with 
the κB containing regions within the CCL2 gene promoter as was observed for the CCL20 
gene promoter (Figures 6B and 6D). By contrast, the COX2 gene retained IL-1β-stimulated 
p65 recruitment in both the presence and absence of p50 overexpression (Figure 6G). 
Moreover, p50 recruitment to the COX2 gene promoter occurred in the absence of IL-1β 
(basal state) and was equivalent to the IL-1β-induced condition during p50 overexpression 
(Figure 6H). Furthermore, p50 overexpression plus IL-1β doubled the amount of p50 bound 
to the COX2 gene promoter (Figure 6H; black bars), consistent with p50 overexpression 
enhancing the expression of the COX2 gene (Figure 5D).
3.1.6 Differential co-activator recruitment to κB target genes in response to IL-1β
Recruitment of co-activator complexes to a given gene promoter is a critical part of the 
transcriptional regulatory process [55]. As a starting point to determine how selectivity of 
NF-κB subunits controls the expression of specific genes in response to IL-1β, we 
investigated the recruitment of three distinct proteins with known co-regulatory function: 
coactivator arginine methyltransferase (CARM1), CREB-binding protein (CBP), and p300. 
The recruitment of each of these proteins was monitored on the CCL20, CCL2, and COX2 
gene promoters. These co-activators were chosen based on their established involvement in 
stimulus-induced transcriptional regulation [56, 57].
Cellular exposure to IL-1β for 15min induced a 4.25 fold increase in p65 binding, but no 
occupancy of CARM1 at the CCL20 gene promoter (Figure 7A). However, p300 and CBP 
were both recruited to the CCL20 promoter region in response to IL-1β (Figure 7A). 
Consistent with a lack of CARM1 occupancy, the CCL20 promoter shows no enrichment in 
H3R17 methylation, a known target of CARM1 (Figure 7B). By contrast, CARM1 is 
enriched at the CCL2 gene promoter after cellular exposure to IL-1β (Figure 7C), which is 
congruent with increased levels of H3R17 methylation (Figure 7D). Interestingly, the CCL2 
gene shows enrichment for p300, but not CBP (Figure 7C). Alternatively, the COX2 
promoter does not show increased occupancy of either p300 or CBP in response to IL-1β. 
However, we do note a higher basal level of CBP (~3-fold above background) associated 
with the COX2 gene promoter, which is unaltered by signaling through the IL-1β pathway 
(Figure 7E). In addition, the IL-1β-mediated recruitment of CARM1 to the COX2 gene is 
also associated with attendant elevations in H3R17 methylation at the corresponding COX2 
proximal promoter region (Figure 7F). Thus, IL-1β-mediated control of NF-κB target genes 
occurs via differential co-activator specificities, which are in turn linked to their specific 
histone post-translational modifications.
3.1.7 Pro-inflammatory cytokines promote cell surface expression of CCR6 in human 
peripheral blood neutrophils
Peripheral blood neutrophils (PBNs) are important innate immune cells that contribute to the 
development of T1DM [41] and are also elevated during obesity [58]. We observed elevated 
expression of chemokines capable of recruiting neutrophils and other immune cells within 
pancreatic islets isolated from obese (db/db) mice relative to their lean (db/+) controls 
(Table 1). In addition, Cox2 and Pges, which are responsible for production of prostaglandin 
E2, are also elevated in obese islets concomitant with a decrease in the expression of the 
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transcription factors MafA, Nkx6.1, and Pdx-1 (Table 1). These data are consistent with a 
decrease in islet transcription factor abundance associated with obesity and T2DM in mice 
and humans [59] and further show that chemokines and other inflammatory genes are 
coordinately upregulated in pancreatic islets during obesity.
Because the CCL20 ligand is a primary response gene induced by IL-1β in rodent and 
human islets and clonal β-cell lines, we next investigated whether human peripheral blood 
neutrophils (PBNs) responded to inflammatory signals by altering their expression of 
specific chemokine receptors, such as CCR6 and CXCR2. To mimic a local inflammatory 
state, human PBNs were exposed to IL-1β, TNF-α, or IFN-γ for 30 minutes. All of these 
cytokines have been linked to islet inflammation, obesity, and/or diabetes [3, 60–63]. We 
detected elevated levels of CCR6 after exposure to each of these pro-inflammatory 
cytokines, with IFN-γ producing the largest increase in CCR6 expression (Figure 8A, C, & 
E). A combination of IL-1β, TNF-α, and IFN-γ did not further induce CCR6 expression over 
the response seen with the individual cytokines (not shown). By contrast, CXCR2 
expression on PBNs was essentially unaltered under identical conditions (Figure 8B, D, & 
F). Thus, obesity is associated with both elevated cytokine [64, 65] and chemokine 
expression (Table 1) within pancreatic islets, which could potentially influence the 
expression of neutrophil chemokine receptors. This change in receptor expression is 
expected to modify the neutrophil capacity to respond to the local microenvironment.
3.1.8 Circulating CCL2 and CCL20 levels are elevated in mouse models of obesity
Obesity is associated with both local and systemic inflammation [66, 67] and CCL2 levels 
are elevated in human obesity [24]. Thus, we first measured CCL2 as a control for 
chemokine elevation during obesity. Using serum obtained from C57BL6/J mice, we 
detected a 3.09-fold increase in circulating CCL2 in mice fed a high-fat diet (containing 
60% kcal from fat) for 18 weeks relative to animals on a 10% fat (kcal) diet (Figure 9A). In 
addition, db/db mice, a genetic model of obesity induced by leptin resistance, also had 3.06-
fold more CCL2 in the serum relative to their lean (db/+) counterparts (Figure 9B).
The expression of the CCL20 gene is enhanced in human islets cultured in the presence of 
palmitate [68], which may indicate a link between elevated CCL20 expression and obesity. 
Thus, we compared serum levels of CCL20 from C57BL6/J mice after 18 weeks on diets 
containing different percentages of their calories from fat. Mice fed 25% (grey bar) or 60% 
fat (black bar) had 1.55-fold and 2.58-fold increases, respectively, in serum CCL20 
abundance when compared to control mice on a diet with 10% fat (Figure 9C). The db/db 
mice, which readily develop obesity on a chow (< 10% kcal from fat) diet, exhibited a 3.18-
fold elevation in serum CCL20 relative to their lean counterparts (db/+; Figure 9D). 
Moreover, histological analysis of islets within the db/db pancreas revealed noticeably 
higher levels of CCL20 protein when compared with islets from db/+ mice (compare Figure 
9E with 9F; notice the increase in non-nuclear punctate staining of CCL20 granules in islets 
from the obese db/db mice). Collectively, these data reveal that the circulating levels of both 
CCL2 and CCL20 are elevated during obesity and that the CCL20 protein is readily 
detectable in pancreatic islets from obese mice.
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The pro-inflammatory cytokine IL-1β is a key contributor to the development of both T1DM 
and T2DM [62, 69]. Decreases in function and mass of the pancreatic islet β-cells are the 
foremost causes of both T1DM and T2DM [2, 70, 71]. IL-1β is a pro-inflammatory 
cytokine, secreted by a variety of immune cells, that elicits powerful transcriptional and 
functional effects on islet β-cells [5, 6, 8, 12, 13]. Children positive for islet autoantibodies, 
indicating a genetic predisposition to diabetes, display elevated circulating IL-1β [72]. In 
addition, IL-1β is also increased in children recently diagnosed with T1DM [73].
Because IL-1β induces a host of chemokine and other inflammatory genes in pancreatic β-
cells, interfering with its activity has been targeted to relieve inflammation-induced tissue 
dysfunction. Interestingly, clinical interventions targeting the IL-1 signaling pathway 
improved islet β-cell function in human subjects with impaired glucose tolerance [74, 75] 
and those with overt diabetes [76] but did not alleviate peripheral insulin resistance in either 
group. This therapeutic outcome could be explained by decreasing the availability of the 
ligand(s) activating IL-1RI, which is highly expressed on islet β-cells relative to other tissues 
[7]. We report here that expression of the CCL20 gene in pancreatic β-cells is exquisitely 
sensitive to IL-1β. In addition, we found that IL-1R activation in β-cells led to differential 
control of the CCL2, CCL20, and COX2 genes via recruitment of precise NF-κB 
transcription factor subunits to specific genomic elements.
Analysis of global transcriptome changes revealed that CCL20 is one of the most highly 
expressed genes in response to pro-inflammatory stimuli [11]. Our present data adds several 
novel and mechanistic results to this original observation, which include: 1) Two distinct 
and functional κB elements, located within 3kb upstream of the transcriptional start site, are 
present in the CCL20 gene promoter. 2) IL-1β induces expression of the CCL20 gene within 
1h and this response does not require new protein synthesis, indicating that CCL20 is a 
primary response gene. 3) The CCL20 gene is a bona fide NF-κB target gene that is 
differentially regulated by the p65 and p50 subunits. 4) The COX2 gene, while highly 
responsive to IL-1β, is regulated by a different mechanism than that for the CCL2 and 
CCL20 genes. 5) PBNs display increased cell surface CCR6, the receptor for CCL20, after 
exposure to the inflammatory cytokines IL-1β, TNF-α, or IFN-γ. 6) CCL20 is elevated in 
the serum of both db/db mice and in C57BL6 mice fed a high-fat diet.
To our knowledge, this is the first study to report elevated circulating CCL20 in two distinct 
mouse models of obesity and insulin resistance. We speculate that obese humans will 
display similar increases in serum CCL20. Because CCL20 promotes chemotaxis of CD4+ 
and CD8+ T-cells [34, 35], dendritic cells [36], B-lymphocytes [37, 38], natural killer (NK) 
cells [39], and neutrophils [38], elevated expression of this chemokine could be a clinical 
marker of obesity-induced inflammation. Many of the aforementioned immune cells are 
known to be associated with T1DM, T2DM or both diseases [41, 77, 78].
Adipocytes, which are a major contributor to glucose homeostasis and endocrine function 
[79], also synthesize CCL20. Interestingly, CCL20 expression in mature adipocytes is 
positively correlated with BMI and lymphocytes infiltrating the adipose tissue express 
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CCR6 [80]. CCR6 is currently the only known receptor for CCL20. Therefore, the rise in 
circulating CCL20 we observe in obese mouse models (Figure 9) could potentially be due to 
several tissue sources, including adipocytes and pancreatic β-cells.
Collectively, these data place CCL20 in a prime position to be a significant contributor to 
the development or progression of both T1DM and T2DM based on circulating levels during 
obesity, direct expression from pancreatic β-cells, and the ability to influence the immune 
cell types associated with both major forms of diabetes. Therefore, the CCL20-CCR6 
interaction should be considered as a potential novel target for therapeutic intervention in 
obesity and diabetes. Indeed, inhibitors of this axis have shown promise in mouse models 
and preclinical trials of other autoimmune diseases [81, 82].
Unlike most chemokine receptors, CCR6 has only one known ligand (i.e., CCL20). We 
found that IL-1β, TNF-α, and IFN-γ were all able to induce CCR6 expression on the surface 
of human neutrophils (Figure 8). This data complements a previous study, which reported on 
a Th17+ subpopulation of human CD4+ T-cells, which were also positive for CCR6 [83]. 
Thus, tissue-derived CCL20 may be impacting several specific immune cell populations in 
the context of autoimmune and auto-inflammatory diseases. In addition to CCL20, IL-1β 
induces the expression of many different chemokines in pancreatic islets and β-cell lines, 
including CCL2, CXCL1, CXCL2, CXCL10, and CCL20 (refs [12–14] and data herein). 
The expression of all of these genes requires specific signaling molecules within the 
IL-1R/NF-κB signaling pathways along with the associated transcription factors.
A key finding in the present study is that the individual gene promoters controlling 
expression of the CCL2 and CCL20 genes display p50 occupancy in the basal 
(unstimulated) state (Fig. 5), indicating a likely repressor function of this subunit in this 
particular context. After IL-1β exposure, p50 is replaced by p65 on the CCL2 and CCL20 
gene promoters prior to the increase in transcript accumulation. However, both p65 and p50 
are recruited to the COX2 gene in response to IL-1β, which is similar to what occurs with 
the CXCL1 and CXCL2 genes [12]. Because the temporal recruitment of p65 is similar 
between all three genes, we speculate that the COX2 gene requires a p65/p50 heterodimer 
for activation while CCL2 and CCL20 transcriptional activation most likely involves p65 
homodimers.
The biological significance of the differential NF-κB subunit usage is not entirely clear at 
the present time but may indicate a constraint on signal-specific co-activator recruitment to 
each gene. Indeed, although CCL2, CCL20, and COX2 are all induced by IL-1β and require 
p65 for their expression, we detected differential co-activator requirements at the promoter 
regions of each of these genes. This may be one way in which timing, specificity, and 
duration of genes involved in the inflammatory response are controlled. If so, it may thus 
allow for selective targeting of individual genes, or groups of genes, by small molecule 
inhibitors of enzymatic activity contained within each particular co-activator protein.
Moreover, our novel data reveals that the CCL2 and CCL20 genes are differentially 
regulated when compared with COX2 and other chemokine genes (e.g., CXCL10). The 
IL-1β-induced increase in CXCL10 transcription is magnified when IFN-γ is present [13]. 
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While CCL20 and CXCL10 are both elevated during obesity [see ref [84] and Fig 1 of the 
present study] and both require NF-κB for increased expression after cellular exposure to 
IL-1β (see Fig. 3 and 4 and ref [13]), CCL20 expression is not sensitive to IFN-γ (Figure 1). 
Thus, based on our work and the work of others, we postulate that dysfunctional islets from 
obese rodents and humans may be due to a decrease in the expression and abundance of 
transcription factors that control islet β-cell function concomitant with a coordinated 
increase in synthesis and secretion of various chemokines (e.g., Table 1). Our observations 
of increased expression of the COX2 and PTGES genes in islets from obese mice (Table 1) 
are also congruent with transgenic expression of COX2 and mPGES promoting losses in 
functional β-cell mass in vivo [85].
In summary, pancreatic β-cells express CCL20 in response to inflammatory signals, such as 
IL-1β, while neutrophils upregulate expression of CCR6, the only known receptor for 
CCL20, in response to several pro-inflammatory cytokines. These findings offer the 
intriguing possibility that the CCL20-CCR6 axis may be a novel therapeutic target to offset 
pathologies either associated with obesity and/or leading to diabetes. Our data suggest that 
therapeutic interventions may be able to target either specific components of the NF-κB 
pathway (to stop overall production of chemokine ligands) or CCL20 signaling through 
CCR6 (e.g., by directly targeting CCR6). Combination therapies aimed at both of these sites 
would also be feasible.
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• CCL20 mRNA and protein are increased by IL-1β in pancreatic [3-cells.
• Induction of CCL20 requires IκKβ, a component of the NF-κB signaling 
pathway.
• p65, a NF-κB transcriptional subunit, is recruited to the CCL20 gene promoter.
• Circulating CCL20 is elevated in mouse models of obesity and insulin 
resistance.
• Human neutrophils elevate CCR6 protein in response to pro-inflammatory 
cytokines.
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Figure 1. IL-1β induces expression of the CCL20 gene in human and rat islets and β-cell lines
A. INS-1E rat insulinoma cells were untreated (NT) or treated with 1ng/mL IL-1β, 100 
U/mL IFN-γ or both cytokines for 3 h. *, P < 0.05 vs. NT, n.s. = not significant. B. Isolated 
islets from Wistar rats were untreated (NT) or treated for 3 h with 10 ng/mL IL-1β, 100 
U/mL IFN-γ or both cytokines. **, P < 0.01 vs. NT, *, P < 0.05 vs. NT, n.s. = not 
significant. C. Human islets were untreated (NT) or stimulated for 3 h with 10 ng/mL IL-1β, 
100 U/mL IFN-γ or both cytokines.*, P < 0.05 vs. NT, n.s. = not significant. D. 832/13 rat 
insulinoma cells were untreated (NT) or treated with 1 ng/mL IL-1β for the indicated times. 
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E. Rat islets were untreated (NT) or stimulated for 1, 2 or 3 h with 10 ng/mL IL-1β. **, P < 
0.01 vs. NT, *, P < 0.05 vs. NT. F. Human islets were untreated (NT) or stimulated for 1, 2 
or 3 h with 10 ng/mL IL-1β. **, P < 0.01 vs. NT, *, P < 0.05 vs. NT. A–F. Transcript data 
are shown as means ± SEM from three individual experiments.
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Figure 2. IL-1β-mediates upregulation of the CCL20 gene through IκKβ, IκBα and p65
A. Schematic representation of −3kb region of the CCL20 promoter, showing the distal and 
proximal κB sites. B. 832/13 cells were transfected with a luciferase reporter construct 
containing −3kb of the CCL20 proximal promoter. 24 h after the transfection cells were 
exposed to IL-1β (1 ng/mL) for 4 h. **, P < 0.01 vs. NT. C. 832/13 cells were transfected 
with the wild-type (WT) CCL20 −3kb promoter- luciferase construct or −3kb promoter-
luciferase constructs containing mutations in either the distal (dNF-κBm) or proximal (pNF-
κBm) NF-κB response elements. 24 h post-transfection cells were untreated or treated for 4 
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h with 1 ng/mL IL-1β (maximal IL-1β response is set at 100%). ***, P < 0.001 vs. WT. B–
C. Promoter activity is shown as means + S.E.M. D. 832/13 cells were pre-treated for 1 h 
with either DMSO (vehicle control) or the indicated concentrations of TPCA. Cells were 
subsequently treated for 3 h with 1 ng/mL IL-1β. ***, P < 0.001 vs. DMSO. E. 832/13 cells 
were transduced with adenoviruses overexpressing β-Galactosidase (βGAL) or IκBα 
superrepressor (SR). After a 24 h exposure to adenovirus, cells were stimulated with 1 
ng/mL IL-1β for 30 mins. Cells were fractionated and immunoblotted to determine relative 
abundance of p65 and IκBα in these respective subcellular fractions. β-Actin served as a 
loading control. Solid arrow= adenovirally overexpressed IκBα; dashed arrow = endogenous 
IκBα. A representative image of two immunoblots is shown in E. F. 832/13 cells were 
transduced with adenoviruses expressing βGAL or IκBαSR Following a 24 h exposure to 
adenoviruses, cells were stimulated for 3 h with 1 ng/mL IL-1β. **, P < 0.01. D–F. Relative 
mRNA abundance of CCL20 is shown. G. 832/13 cells were exposed to adenoviruses 
expressing either βGAL or IκBαSR for 12 h, followed by 12 h stimulation with 1 ng/mL 
IL-1β. CCL20 release into the media was quantified by ELISA assay and normalized to total 
protein content. **, P < 0.01 vs. βGAL-IL-1β control, ***, P < 0.001 vs. βGAL-IL-1β 
control. For promoter activity, mRNA and ELISA experiments three individual replicates 
were generated and expressed as means ± SEM.
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Figure 3. p50 is displaced from CCL2 and CCL20, but recruited to the COX2 gene promoter, in 
response to IL-1β
A–D. 832/13 cells were untreated (NT) or stimulated with 1 ng/mL IL-1β for 15, 30 or 60 
mins. ChIP assays were performed to determine relative occupancy of p65 (middle panels) 
and p50 (right panels) on the CCL20 proximal (A) and distal promoter (B), and on the CCL2 
(C) and COX2 (D) promoters. **, P < 0.01 vs. NT, *, P < 0.05 vs. NT. Data are shown as 
means ± SEM from 3-4 individual experiments. A- D left panels are schematic 
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representations of the indicated promoters. PCR primers amplifying a given gene promoter 
region are denoted schematically by the left and right facing arrows.
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Figure 4. Restricting p65 nuclear entry prevents the displacement of p50 from chemokine gene 
promoters
A–H. 832/13 cells transduced with adenoviruses overexpressing βGAL or IκBαSR 24 h post-
transduction cells were untreated (NT) or stimulated with 1 ng/mL IL-1β for 15 mins. ChIP 
assays were performed to determine relative occupancy of p65 (A, C, E, G) and p50 (B, D, 
F, H) on the CCL20 proximal (A, B) and distal promoters (C, D), and on the CCL2 (E, F) 
and COX2 (G, H) promoters. **, P < 0.01 vs. βGAL (IL-1β), *, P < 0.05 vs. βGAL (IL-1β), 
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#P < 0.1 vs. βGAL (IL-1β). ChIP assay data are expressed as means ± SEM from 3–4 
individual experiments.
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Figure 5. p50 overexpression diminishes CCL2 and CCL20 gene expression, but enhances 
expression of COX2, in response to IL-1β
A. 832/13 cells were transduced with adenoviruses expressing either βGAL or five 
increasing concentrations of NF-κB1. 24 h post-transduction whole cell lysates were 
harvested and immunoblotted for p50/p105 (expressed from the NF-κB1 gene) with p65 and 
β-Actin shown as the loading controls. The image shown is representative of two 
independent experiments. B–D. 832/13 cells were exposed to adenoviruses expressing 
βGAL or increasing concentrations of p50 (as shown in immunoblot in A) for 24 h. Cells 
were then exposed to 1 ng/mL IL-1β for 3 h. Relative mRNA abundance of CCL20 (B), 
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CCL2 (C) and COX2 (D) are shown. ***, P < 0.001 vs. βGAL, **, P < 0.01 vs. βGAL, *, P 
< 0.05 vs. βGAL. E. 832/13 cells were transfected with −3kb CCL20 promoter-luciferase 
construct. 4 h post-transfection cells were transduced with adenoviruses expressing either 
βGAL or p50 adenovirus overnight, then stimulated for 4 h with 1 ng/mL IL-1β. ***, P < 
0.001 vs. βGAL. F. Following a 12 h incubation with adenoviruses expressing βGAL or p50, 
832/13 cells were untreated (NT) or stimulated with 1 ng/mL IL-1β for an additional 12 h. 
CCL20 release into the media is shown. **, P < 0.01 vs. βGAL (IL-1β). G. 832/13 cells 
were transduced with either βGAL or p50 for a 12 h exposure, followed by a 30 min 
stimulation with 1 ng/mL IL-1β. Cells were fractionated and immunoblots completed to 
determine the subcellular location of p65 and p50. β-Actin served as the loading control. The 
experiment in G was repeated on two separate occasions, and a representative image is 
shown. Promoter activity, mRNA abundance and ELISA data are expressed as means ± 
SEM from 3 individual experiments.
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Figure 6. p50 overexpression blocks recruitment of p65 to the CCL2 and CCL20, but not COX2, 
gene promoters
A–H. 832/13 cells were transduced with adenoviruses overexpressing βGAL or p50 (NF-
κB1). 24 h post-transduction cells were untreated (NT) or stimulated with 1 ng/mL IL-1β for 
15 mins. ChIP assays were performed to determine relative occupancy of p65 (A, C, E, G) 
and p50 (B, D, F, H) on the CCL20 proximal (A, B) and distal promoters (C, D), and on the 
CCL2 (E, F) and COX2 (G, H) promoters. **, P < 0.01 vs. βGAL (IL-1β), *, P < 0.05 vs. 
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βGAL (IL-1β), #P < 0.1 vs. βGAL (IL-1β). ChIP data are shown as means ± SEM from 3 
individual experiments.
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Figure 7. Differential co-activator recruitment in response to IL-1β
A, C, E. 832/13 cells were untreated (NT) or stimulated with 1 ng/mL IL-1β for 15 mins. 
ChIP assays were used to determine relative occupancy of p65, CARM1, p300 and CBP on 
the CCL20 proximal promoter (A), and on the CCL2 (C) and COX2 (E) promoters. ***, P < 
0.001 vs. NT, **, P < 0.01 vs. NT, *, P < 0.05 vs. NT. B, D, F. 832/13 cells were untreated 
(NT) or stimulated with 1 ng/mL IL-1β for 15, 30 or 60 mins. ChIP assay of histone H3 
dimethylated on Arginine 17 (H3R17me2) is shown at the CCL20 proximal promoter (B), 
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and on the CCL2 (D) and COX2 (F) promoters. *, P < 0.05 vs. NT, #P < 0.1 vs. NT. Data 
are shown as means ± SEM from 3 individual experiments.
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Figure 8. Exposure to inflammatory cytokines increases expression of CCR6 on PBNs
Human PBNs were stimulated with 1ng/ml of IL-1β, TNF-α, or IFN-γ or unstimulated for 
30min at 37°C. Cell surface detection of CCR6 (A, C, E) and CXCR2 (B, D, F) is shown. 
The blue line represents cell surface expression during the unstimulated state while the red 
line represents expression after cytokine stimulation. This is a representative experiment 
from 5 total experiments.
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Figure 9. CCL20 is elevated in pancreatic islets and serum from obese mice
Serum samples from 24 week-old C57BL6/J mice fed for 18 weeks with the diets containing 
the indicated fat content (A,C) or 8 week old db/db mice fed a diet containing 6% fat (B,D) 
were analyzed for CCL2 (A,B) and CCL20 (C,D) protein levels by ELISA. Data represent 
means + S.E.M. from 6-8 animals per group. Pancreata isolated from 8 week old lean (db/+; 
panel E) or obese (db/db; panel F) mice were stained for the presence of CCL20 and 
counterstained with hematoxylin to identify nuclei. Note the increase in punctate non-
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nuclear granules indicating immunoreactive CCL20 in the obese (db/db) mice (panel F). **, 
P < 0.01, *, P < 0.05, n.s. = not significant.
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Table 1
Islets from obese (db/db) mice display enhanced expression of inflammatory genes and a 
decrease in the expression of transcription factors that regulate β-cell identity
Expression of genes associated with inflammation are shown as the fold increase in obese islets relative to 
lean (middle column), while islet β-cell transcription factor abundance is given as the percent decrease in 
obese islets relative to the lean controls (right hand column).
Gene Fold Increase
(Obese/Lean)
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